Ruediger Weseloh

Mr Weseloh is an Executive Director of Business Development at EMD Serono, Inc, Rockland, MA, USA., where over a period of 19 years he has led more than 80 transactions for the health care division of its parent company Merck KGaA, Darmstadt, Germany. Completed deals across the drug development value chain were in the fields of Oncology, Rheumatology, Neurodegenerative diseases, and Fertility. Before joining Merck KGaA, he spent five years as a Biotech/Pharma Equity Analyst, at Gontard and Metallbank AG, Frankfurt, and Sal. Oppenheim, Cologne/Frankfurt, as well as three years as a Postdoc at the Max-Planck-Institute for Experimental Medicine in Goettingen.